These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 1376136)

  • 1. HIV-1 env, nef, and gag-specific T-cell immunity in mice: conserved epitopes in nef p27 and gag p25 proteins.
    Michel F; Hoffenbach A; Froussard P; Langlade-Demoyen P; Kaczorek M; Kieny MP; Plata F
    AIDS Res Hum Retroviruses; 1992 Apr; 8(4):469-78. PubMed ID: 1376136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.
    Thakar MR; Bhonge LS; Lakhashe SK; Shankarkumar U; Sane SS; Kulkarni SS; Mahajan BA; Paranjape RS
    J Infect Dis; 2005 Sep; 192(5):749-59. PubMed ID: 16088824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of HIV peptide epitopes by a novel algorithm.
    Roberts CG; Meister GE; Jesdale BM; Lieberman J; Berzofsky JA; De Groot AS
    AIDS Res Hum Retroviruses; 1996 May; 12(7):593-610. PubMed ID: 8743085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.
    Wilson SE; Pedersen SL; Kunich JC; Wilkins VL; Mann DL; Mazzara GP; Tartaglia J; Celum CL; Sheppard HW
    AIDS Res Hum Retroviruses; 1998 Jul; 14(11):925-37. PubMed ID: 9686639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
    Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
    Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple subsets of HIV-specific cytotoxic T lymphocytes in humans and in mice.
    Chenciner N; Michel F; Dadaglio G; Langlade-Demoyen P; Hoffenbach A; Leroux A; Garcia-Pons F; Rautmann G; Guy B; Guillon JM
    Eur J Immunol; 1989 Sep; 19(9):1537-44. PubMed ID: 2676560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.
    Gahery H; Daniel N; Charmeteau B; Ourth L; Jackson A; Andrieu M; Choppin J; Salmon D; Pialoux G; Guillet JG
    AIDS Res Hum Retroviruses; 2006 Jul; 22(7):684-94. PubMed ID: 16831093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nef and Gag synthetic peptide priming of antibody responses to HIV type 1 antigens in mice and primates.
    Vaslin B; Claverie JM; Benveniste O; Barre-Sinoussi FC; Dormont D
    AIDS Res Hum Retroviruses; 1994 Oct; 10(10):1241-50. PubMed ID: 7531460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboxyl-terminal and central regions of human immunodeficiency virus-1 NEF recognized by cytotoxic T lymphocytes from lymphoid organs. An in vitro limiting dilution analysis.
    Hadida F; Parrot A; Kieny MP; Sadat-Sowti B; Mayaud C; Debre P; Autran B
    J Clin Invest; 1992 Jan; 89(1):53-60. PubMed ID: 1370302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current approaches to vaccination against human immunodeficiency viruses.
    Gluckman JC; Yagello M; Bahraoui E; Girard M
    Allergol Immunopathol (Madr); 1991; 19(1):11-3. PubMed ID: 1719790
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection.
    Zheng NN; McElrath MJ; Sow PS; Hawes SE; Diallo-Agne H; Stern JE; Li F; Mesher AL; Robinson AD; Gottlieb GS; Huang Y; Kiviat NB
    J Virol; 2007 Sep; 81(17):9061-71. PubMed ID: 17582003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients.
    Durali D; Morvan J; Letourneur F; Schmitt D; Guegan N; Dalod M; Saragosti S; Sicard D; Levy JP; Gomard E
    J Virol; 1998 May; 72(5):3547-53. PubMed ID: 9557634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1)--II. Synthetic peptides linked to HIV-1 carrier proteins gag and nef.
    Neurath AR; Strick N; Kolbe H; Kieny MP; Girard M; Jiang S
    Mol Immunol; 1991 Sep; 28(9):965-73. PubMed ID: 1717841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine-induced CD4+ T cells against the simian immunodeficiency virus gag protein. Epitope specificity and relevance to protective immunity.
    Mills KH; Barnard AL; Williams M; Page M; Ling C; Stott EJ; Silvera P; Taffs F; Kingsman AS; Adams SE
    J Immunol; 1991 Nov; 147(10):3560-7. PubMed ID: 1719081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study of the antigenic structure of human immunodeficiency virus using synthetic peptides].
    Ivanov VS; Chikin LD; Suvorova ZK; Kozhich AT; Ivanov VT
    Bioorg Khim; 1992 Jun; 18(6):784-93. PubMed ID: 1384509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Envelope protein and p18(IIIB) peptide recognized by cytotoxic T lymphocytes from humans immunized with human immunodeficiency virus envelope.
    Achour A; Picard O; Mbika JP; Willer A; Snart R; Bizzini B; Carelli C; Burny A; Zagury D
    Vaccine; 1993; 11(7):609-701. PubMed ID: 7688170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low or no antibody responses to human immunodeficiency virus type 1 Nef in infected carriers with subtype E, in contrast to subtype B that showed antibodies preferentially recognizing subtype-specific Nef epitopes.
    Komoto S; Kinomoto M; Ibrahim MS; Zhong Q; Auwanit W; Ayuthaya PI; Otake T; Mori H; Oishi I; Kurosu T; Takahashi H; Mukai T; Ikuta K
    Vaccine; 2001 Apr; 19(20-22):3019-32. PubMed ID: 11282214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus.
    Khattar SK; Palaniyandi S; Samal S; LaBranche CC; Montefiori DC; Zhu X; Samal SK
    Hum Vaccin Immunother; 2015; 11(2):504-15. PubMed ID: 25695657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-mediated immune proliferative responses to HIV-1 of chimpanzees vaccinated with different vaccinia recombinant viruses.
    Van Eendenburg JP; Yagello M; Girard M; Kieny MP; Lecocq JP; Muchmore E; Fultz PN; Riviere Y; Montagnier L; Gluckman JC
    AIDS Res Hum Retroviruses; 1989 Feb; 5(1):41-50. PubMed ID: 2470398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.